Is Shire worth a 25% premium?

Can Shire weather the upcoming loss of Adderall XR to the off-patent wildnerness? Company execs say it can: They point out that 60 percent of the company's revenues derive from other products. And they say Vyvase, their new ADHD med, will pick up the Adderall slack--despite the fact that its uptake so far hasn't met expectations. But as Barron's points out, Shire is trading now at 15 times earnings, a 25 percent premium to the current industry multiple of 12 times. If the FDA doesn't listen to Shire's petition--which calls for XR copycats to undergo clinical trials--then generics will hit the market next year. And if Vyvanse doesn't step up to the plate, "Shire wouldn't merit its 25 percent premium," Barron's bluntly states. That's a lot of "ifs"--on either side.

- see the Barron's analysis

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.